House Bill 897
By: Representatives Au of the 50th, Hugley of the 141st, Park of the 107th, Miller of the 62nd,
Frye of the 122nd, and others
A BILL TO BE ENTITLED
AN ACT
To amend Chapter 4 of Title 49 of the Official Code of Georgia Annotated, relating to public
assistance, so as to make insulin accessible to individuals who are in urgent need of a
short-term affordable insulin supply; to provide for a short title; to provide for definitions;
to require a pharmacy to dispense a 30 day supply of insulin to an eligible individual through
the Urgent Insulin Safety Net Program; to allow a pharmacy to collect a copayment for
insulin dispensed through such program; to provide for a pharmacy to submit a claim for
payment or a replacement supply after dispensing insulin through such program; to require
a manufacturer to reimburse or resupply a pharmacy dispensing insulin through such
program; to provide for a pharmacy to dispense one additional short-term affordable urgent
insulin supply under certain conditions; to require the Department of Community Health to
develop an application form, an information sheet, and satisfaction surveys regarding such
program; to require a manufacturer of insulin to establish procedures to make insulin
available under such program; to provide for enforcement, penalties, and appellate
procedures; to provide for reporting; to provide for related matters; to provide for an effective
date; to repeal conflicting laws; and for other purposes.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION 1.
Chapter 4 of Title 49 of the Official Code of Georgia Annotated, relating to public assistance,
is amended by adding a new article to read as follows:
<ins>"ARTICLE 10
49-4-200.
This article shall be known and may be cited as the 'Urgent Insulin Safety Net Program
Act.'
49-4-201.
As used in this article, the term:
(1) 'Board' means the State Board of Pharmacy.
(2) 'Department' means the Department of Community Health.
(3) 'Eligible individual' means an individual qualified for assistance under the program
as provided in Code Section 49-4-204.
(4) 'Insulin' means various types of insulin analogs and insulin-like medications,
regardless of activation period or whether the solution is mixed before or after
dispensation. An insulin product is exempt from the provisions of this article if the
wholesale acquisition cost of the insulin is $8.00 or less per milliliter or applicable
National Council for Prescription Drug Plan billing unit for the entire assessment time
period, adjusted annually based on the Consumer Price Index.
(5) 'Manufacturer' means a manufacturer engaged in the production of insulin that is
self-administered on an outpatient basis. Such term shall not include a manufacturer with
an annual gross revenue of $2 million or less from insulin sales in this state.
(6) 'Pharmacy' shall have the same meaning as provided in Code Section 26-4-5.
(7) 'Program' means the Urgent Insulin Safety Net Program as provided for in this article.
</ins>
<ins>(8) 'Proper identification' means any document issued by a governmental agency
containing a description of the individual, such individual's photograph, or both, and
giving such individual's date of birth and includes, without being limited to, a passport,
military identification card, driver's license, or an identification card authorized under
Code Sections 40-5-100 through 40-5-104. Proper identification shall not include a birth
certificate.
(9) 'Urgent need of insulin' means having readily available for use less than a seven-day
supply of insulin and in need of insulin in order to avoid the likelihood of suffering
significant health consequences.
49-4-202.
(a) Upon receipt of a completed, signed, and dated application form, as provided for in
Code Section 49-4-204, proof of proper identification, and a copy of a current valid insulin
prescription, a pharmacy shall dispense one 30 day supply of insulin to an eligible
individual in urgent need of insulin; provided, however, that a pharmacy may dispense one
additional 30 day supply of insulin within a 12 month period to an eligible individual as
provided in Code Section 49-4-203.
(b) The pharmacy may collect a copayment from the individual to whom insulin was
dispensed through the program to cover such pharmacy's costs of processing and
dispensing insulin as part of the program in an amount not to exceed $35.00 for the 30 day
supply of insulin dispensed.
(c) The pharmacy shall notify the healthcare provider who issued the insulin prescription
for the eligible individual no later than 72 hours after the insulin is dispensed.
(d) The pharmacy shall submit to the manufacturer of the dispensed insulin product or to
the manufacturer's vendor a claim for payment that conforms with the National Council for
Prescription Drug Program standards for electronic claims processing. The manufacturer
shall timely reimburse the pharmacy in an amount that covers the pharmacy's acquisition
</ins>
<ins>cost for the insulin and shall timely send the pharmacy a replacement supply of the same
insulin dispensed under the program.
(e) When the pharmacy dispenses the insulin to the eligible individual, the pharmacy shall
also provide an information sheet and a survey, as provided for in Code Sections 49-4-205
and 49-4-206, respectively.
(f) The pharmacy shall retain a copy of submitted applications for reporting and auditing
purposes.
49-4-203.
(a) A pharmacy shall dispense one additional 30 day supply of insulin to an eligible
individual in urgent need of insulin within a 12 month period if such individual has applied
for medical assistance, Georgia Medicaid, or PeachCare for Kids, and has not been
determined eligible or has been determined eligible and coverage has not become effective.
(b) To access one additional 30 day supply of insulin, such eligible individual shall attest
to the pharmacy that the individual meets the requirements of subsection (a) of this Code
section and shall be in compliance with the requirements provided in Code
Section 49-4-204.
49-4-204.
(a) To be deemed eligible for services under this article, an individual shall attest on an
application form as provided for in subsection (b) of this Code section that the individual:
(1) Is a resident of this state;
(2) Is not enrolled in any medical assistance or other health coverage or prescription drug
coverage program that limits such enrollee's total amount of cost-sharing for a 30 day
supply of insulin, including copayments, deductibles, or coinsurance, to $75.00 or less,
regardless of the type or amount of insulin prescribed;
</ins>
<ins>(3) Has not received insulin through the program within the previous 12 months, except
as provided in Code Section 49-4-203; and
(4) Has an urgent need of insulin.
(b) The department shall develop and make available on its website an application form
for the program.
49-4-205.
(a) The department, in coordination with the board, shall develop an information sheet that
shall include, but shall not be limited to:
(1) A description of the program, including how to access it;
(2) Information on applying for medical assistance;
(3) Information on applying for a qualified health benefit plan offered through the
exchange as defined in Code Section 33-23-201; and
(4) Information on accessing healthcare providers who participate in prescription drug
discount programs, including providers who are authorized to participate in the 340B
program under section 340B of the federal Public Health Service Act, 42 U.S.C.
Section 256b, as amended.
(b) The department shall post the information sheet provided for in subsection (a) of this
Code section on its website.
49-4-206.
(a) The department, in coordination with the board, shall develop a survey to assess an
eligible individual's satisfaction with the program, including:
(1) Adequacy of information available and provided to individuals;
(2) Accessibility to insulin; and
(3) Individual's ability to access affordable insulin.
</ins>
<ins>(b) The department, in coordination with the board, shall develop a survey to assess a
pharmacy's satisfaction with the program, including:
(1) Timeliness of reimbursement from the manufacturers for insulin dispensed through
the program;
(2) Ease in submitting claims and insulin product orders to the manufacturers; and
(3) Timeliness of receiving insulin replacement orders from the manufacturers.
(c) The department shall post the surveys provided for in subsections (a) and (b) of this
Code section on its website.
49-4-207.
Each manufacturer shall:
(1) Establish procedures to make insulin available in accordance with this article through
pharmacies to eligible individuals who are in urgent need of insulin;
(2) Establish a hotline to provide information on the program and shall list on its website
information about the program; and
(3) Provide for dedicated personnel to promptly respond to individuals, pharmacies, and
healthcare providers and the department.
49-4-208.
(a) Any person who by means of a false statement, failure to disclose information, or
impersonation, or by other fraudulent device, obtains or attempts to obtain any assistance,
benefit, or payment under this article to which such person is not entitled shall be guilty of
a misdemeanor; provided, however, that if the value of the assistance so obtained exceeds
$1,500.00, such person shall be guilty of a felony.
(b)(1) If a manufacturer fails to comply with the provisions of this article, the department
may assess an administrative penalty of $200,000.00 per month of such noncompliance.
</ins>
<ins>(2) Such penalty shall increase to $400,000.00 per month if the manufacturer continues
to be in noncompliance after six months and shall increase to $600,000.00 per month if
the manufacturer continues to be in noncompliance after one year.
(3) The penalty shall remain at $600,000.00 per month for as long as the manufacturer
continues in noncompliance.
(c) An individual or entity that is aggrieved by the action of the department pursuant to
subsection (a) or (b) of this Code section shall be entitled to a hearing conducted in
accordance with Chapter 13 of Title 50, the 'Georgia Administrative Procedure Act.'
49-4-209.
(a) By July 1, 2026, and every July 1 thereafter, each manufacturer shall report to the
department the following information for the preceding calendar year:
(1) The number of Georgia residents who accessed and received insulin through the
program;
(2) The total value of the insulin, determined by the wholesale acquisition cost of the
insulin, provided by the manufacturer for the program;
(3) The adequacy and timeliness of the manufacturer in responding to a pharmacy
requesting reimbursement or resupply of insulin dispensed through the program;
(4) Any administrative penalties assessed under Code Section 49-4-208; and
(5) Any additional information deemed necessary by the department.
(b) By July 1, 2026, and every July 1 thereafter, a pharmacy that received any applications
for the program shall report to the department the following information for the preceding
calendar year:
(1) The number of applications for an urgent insulin supply received and the number of
applications for additional urgent insulin supply received;
(2) The reasons for determinations of ineligibility;
(3) The amount of insulin dispensed through the program;
</ins>
<ins>(4) The average and total amount of copayment collected from individuals;
(5) The timeliness of manufacturers' responses to requests for payment and re-supply of
insulin; and
(6) Any additional information deemed necessary by the department.
(c) By August 15, 2027, and every August 15 thereafter, the department shall submit to
the General Assembly a report regarding the implementation of the program under this
article. Such report shall include the following information for the preceding year:
(1) The data collected under subsections (a) and (b) of this Code section;
(2) The results of the satisfaction surveys provided for in Code Section 49-4-206; and
(3) Any additional information deemed necessary by the department to assess the
effectiveness of the implementation of the program."
</ins> SECTION 2.
This Act shall become effective July 1, 2025.
SECTION 3.
All laws and parts of laws in conflict with this Act are repealed.